-
Aquaro S, Calio R, Balzarini J. Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir[J]. Antivir Res, 2002, 55(): 209-225. doi: 10.1016/S0166-3542(02)00052-9
-
Baldwin C E, Sanders R W, Berkhout B. Inhibiting HIV-1 entry with fusion inhibitors[J]. Curr Med Chem, 2003, 10(): 1633-1642. doi: 10.2174/0929867033457124
-
Beisswanger R, Corbeil D, Vannier C. Existence of distinct tyrosylprotein sulfotransferase-2[J]. Proc Natl Acad Sci USA, 1998, 95(): 11134-11139. doi: 10.1073/pnas.95.19.11134
-
Burton D R, Pyati J, Koduri R. Efficient neutralization of primary isolates of HIV-1 by a recombi-nant human monoclonal antibody[J]. Science, 1994, 266(): 1024-1027. doi: 10.1126/science.7973652
-
Cavacini L A, Emes C L, Wisnewski A V. Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41[J]. AIDS Res Hum Retroviruses, 1998, 14(): 1271-1280. doi: 10.1089/aid.1998.14.1271
-
Chan D C, Kim P S. HIV entry and its inhibition[J]. Cell, 1998, 93(): 681-684. doi: 10.1016/S0092-8674(00)81430-0
-
Choe H, Li W, Wright P L. Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120[J]. Cell, 2003, 114(): 161-170. doi: 10.1016/S0092-8674(03)00508-7
-
Dorfman T, Moore M J, Guth A C. A tyrosine-sulfated peptide derived from the heavy-chain CDR3 region of an HIV-1-neutralizing antibody binds gp120 and inhibits HIV-1 infection[J]. J Biol Chem, 2006, 281(): 28529-28535. doi: 10.1074/jbc.M602732200
-
Frankel S S, Steinman R M, Michael N L. Neutralizing monoclonal antibodies block human immu-nodeficiency virus type 1 infection of dendritic cells and transmission to T cells[J]. J Virol, 1998, 72(): 9788-9794.
-
Ganesh L, Leung K, Lore K. Infection of specific dendritic cells by CCR5-tropic human immu-nodeficiency virus type 1 promotes cell-mediated transmis-sion of virus resistant to broadly neutralizing antibodies[J]. J Virol, 2004, 78(): 11980-11987. doi: 10.1128/JVI.78.21.11980-11987.2004
-
Gaschen B, Korber B, Foley D T. 1999. Global variation in the HIV-1 V3 region. In: Human Retroviruses and AIDS (Kuiken C, Foley B, Hahn B, et al. ed), Los Alamos: Los Alamos National Lab. p594-602.
-
Gorny M K, Conley A J, Karwowska S. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody[J]. J Virol, 1992, 66(): 7538-7542.
-
Gorny M K, Xu JY, Karwowska , S .. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120[J]. J Immunol, 1993, 150(): 635-643.
-
Hioe C E, Xu S, Chigurupati P. Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies[J]. Int Immunol, 1997, 9(): 1281-1290. doi: 10.1093/intimm/9.9.1281
-
Holl V, Hemmerter S, Burrer R. Involvement of FcγRI (CD64) in the mechanism of HIV-1 inhibition by polyclonal IgG purified from infected patients in cultured monocyte-derived macrophages[J]. J Immunol, 2004, 173(): 6274-6283. doi: 10.4049/jimmunol.173.10.6274
-
Holl V, Peressin M, Decoville T. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrop-hages and immature dendritic cells[J]. J Virol, 2006, 80(): 6177-6181. doi: 10.1128/JVI.02625-05
-
Holl V, Peressin M, Decoville T. Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation[J]. Blood, 2006, 107(): 4466-4474. doi: 10.1182/blood-2005-08-3490
-
Jones P L, Korte T, Blumenthal R. Conformational changes in cell surface HIV-1 envelope glycoproteins are triggered by cooperation between cell surface CD4 and co-receptors[J]. J Biol Chem, 1998, 273(): 404-409. doi: 10.1074/jbc.273.1.404
-
Lee S J, Arora R, Bull L M. A non-neutralizing anti-HIV-1 antibody turns into a broad neutralizing antibody when expressed on the surface of HIV-1-susceptible cells (Ⅱ): inhibition of HIV-1 captured and transferred by DC-SIGN[J]. AIDS Res Hum Retro-viruses, 2006, 22(): 874-883. doi: 10.1089/aid.2006.22.874
-
Lee S J, Gauza L, Yao J. A non-neutralizing anti-HIV-1 antibody turns into a neutralizing antibody by expressing it on the surface of HIV-1-susceptible cells – a new way to fight HIV-1[J]. J Immunol, 2004, 173(): 4618-4626. doi: 10.4049/jimmunol.173.7.4618
-
Larsson M. HIV-1 and the hijacking of dendritic cells: a tug of war[J]. Springer Semin Immunopathol, 2005, 26(): 309-328. doi: 10.1007/s00281-004-0178-y
-
McDonald D, Wu L, Bohks S M. Recruitment of HIV and its receptors to dendritic cell-T cell junctions[J]. Science, 2003, 300(): 1295-1297. doi: 10.1126/science.1084238
-
Miranda L R, Duval M, Doherty H. The neutralization properties of a HIV-specific antibody are markedly altered by glycosylation events outside the antigen-binding domain[J]. J Immunol, 2007, 178(): 7132-7138. doi: 10.4049/jimmunol.178.11.7132
-
Montefiori D C, Hill T S, Vo H T. Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immu-nodeficiency virus type 1 infection[J]. J Virol, 2001, 75(): 10200-10207. doi: 10.1128/JVI.75.21.10200-10207.2001
-
Moore J P, Cao Y, Qing L. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120[J]. J Virol, 1995, 69(): 101-109.
-
Muster T, Guinea R, Trkola A. Cross-neutralizing activity against divergent human immunodefi-ciency virus type 1 isolates induced by the gp41 sequence ELDKWAS[J]. J Virol, 1994, 68(): 4031-4034.
-
Muster T, Steindl F, Purtscher M. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1[J]. J Virol, 1993, 67(): 6642-6647.
-
Nyambi , P. N.. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M[J]. J. Virol, 2000, 74(): 7096-7107. doi: 10.1128/JVI.74.15.7096-7107.2000
-
Ouyang Y, Lane W S, Moore K L. Tyrosylprotein sulfotransferase: purification and molecular cloning of an enzyme that catalyzes tyrosine O-sulfation, a common posttranslational modification of eukaryotic proteins[J]. Proc Natl Acad Sci USA, 1998, 95(): 2896-2901. doi: 10.1073/pnas.95.6.2896
-
Pantophlet R, Burton D R. Gp120: target for neutralizing HIV-1 antibodies[J]. Annu Rev Immunol, 2006, 24(): 739-769. doi: 10.1146/annurev.immunol.24.021605.090557
-
Poignard P, Saphire E O, Parren P WHI. GP120: Biologic aspects of structural features[J]. Annu Rev Immunol, 2001, 19(): 253-274. doi: 10.1146/annurev.immunol.19.1.253
-
Rosenquist G L, Nicholas H B Jr. Analysis of sequence requirements for protein tyrosine sulfation[J]. Protein Sci, 1993, 2(): 215-222.
-
Sattentau Q J, Moore J P, Vignaux F. Conformational changes induced in the envelope glycopro-teins of the human and simian immunodeficiency viruses by soluble receptor binding[J]. J Virol, 1993, 67(): 7383-7393.
-
Sattentau Q J, Zollar-Pazner S, Poignard P. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules[J]. Virology, 1995, 206(): 713-717. doi: 10.1016/S0042-6822(95)80094-8
-
Stiegler G, Kunert R, Purtscher M. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodefi-ciency virus type 1[J]. AIDS Res Hum Retroviruses, 2001, 17(): 1757-1765. doi: 10.1089/08892220152741450
-
Takeda S N, Dorfman N A, Robert-Guroff M. Two-phase approach for the expression of high-affinity human anti-human immunodeficiency virus imm-unoglobulin Fab domain in E. coli[J]. Hybridoma, 1995, 14(): 9-18. doi: 10.1089/hyb.1995.14.9
-
Trkola A, Pomales A B, Yuan H. Cross-clade neutralization of primary isolates of human immunodefi-ciency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG[J]. J Virol, 1995, 69(): 6609-6617.
-
Trkola A, Purtscher M, Muster T. Human monoclonal antibody 2G12 defines a distinctive neutrali-zation epitope on the gp120 glycoprotein of human immu-nodeficiency virus type 1[J]. J Virol, 1996, 70(): 1100-1108.
-
Vujcic L K, Quinnan G V Jr. Preparation and characterization of human HIV type 1 neutralizing reference sera[J]. AIDS Res Hum Retroviruses, 1995, 11(): 783-787. doi: 10.1089/aid.1995.11.783
-
Weissenhorn W, Dessen A, Harrison S. Atomic structure of the ectodomain from HIV-1 gp41[J]. Nature, 1997, 387(): 426-430. doi: 10.1038/387426a0
-
Wilflingseder D, Banki Z, Garcia E. IgG opsonization of HIV impedes provirus formation in and infection of dendritic cells and subsequent long-term transfer to T cells[J]. J Immunol, 2007, 78(): 7840-7848.
-
Wyatt R, Sodroski J. The HIV-1 envelope glycopro-teins: fusogens, antigens and immunogens[J]. Science, 1998, 280(): 1884-1888. doi: 10.1126/science.280.5371.1884
-
Xu J Y, Gorny M, Palker T. Epitope mapping of two immunodominant domains of gp41, the transmem-brane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies[J]. J Virol, 1991, 65(): 4832-4838.
-
Zhou P, Goldstein S, Devadas K. Cells transfected with a non-neutralizing antibody gene are resistant to HIV infection: targeting the endoplasmic reticulum and trans-golgi network[J]. J Immunol, 1998, 160(): 1489-1496.
-
Zwick M B, Labrijn A F, Wang M. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41[J]. J Virol, 2001, 75(): 10892-10905. doi: 10.1128/JVI.75.22.10892-10905.2001